Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)

CAPS Rating: 3 out of 5

A pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs used in the treatment of a variety of gastrointestinal diseases, which are those affecting the digestive tract.

Results 1 - 20 of 20

Recs

0
Member Avatar TMFDeej (99.26) Submitted: 11/8/2014 12:12:06 PM : Outperform Start Price: $91.00 SLXP Score: +26.59

Yes the CFO was a crook who cooked the books, but there is real value here and Salix should now become an interesting takeover target.

Jason

Recs

0
Member Avatar smbren (< 20) Submitted: 9/17/2014 9:10:08 PM : Outperform Start Price: $161.08 SLXP Score: -29.14

Perhaps I am partial, this is my top holding with a little more than 25% of my portfolio.

Tax strategies being taken are a benefit, although I don't like seeing this as a US citizen.
If you follow where they stand with products, they have a good standing. And there is benefit with the upcoming merger as can be read in many articles.

downside, well, it is pharma. pharma can have some nasty swings when it comes to negative responses from the FDA. But this is a larger pharma that can withstand a product delay.

Recs

0
Member Avatar Jamanji (77.75) Submitted: 6/16/2011 4:34:27 PM : Outperform Start Price: $35.46 SLXP Score: +164.06

Barron 6/15/11

Recs

0
Member Avatar cbbutton (< 20) Submitted: 7/19/2010 6:09:22 PM : Outperform Start Price: $42.24 SLXP Score: +80.44

strong pipline withhuge potential

Recs

1
Member Avatar Eversar (97.67) Submitted: 2/22/2010 5:02:38 PM : Outperform Start Price: $28.23 SLXP Score: +222.35

Unusually high call volume at $25, $30, & $35 for 3/10

Recs

0
Member Avatar michaeltbryant (< 20) Submitted: 9/15/2009 2:35:40 AM : Outperform Start Price: $19.71 SLXP Score: +388.60

Near term catalyst - Positive results

Recs

0
Member Avatar LexTNZorro (78.08) Submitted: 5/9/2009 5:20:59 PM : Outperform Start Price: $9.90 SLXP Score: +934.12

http://seekingalpha.com/article/136379-fda-clinical-trial-calendar-updates-wye-svnt-amrn-isis-slxp-somx?source=feed

Recs

0
Member Avatar FutbalRef (< 20) Submitted: 9/5/2008 2:49:03 PM : Outperform Start Price: $6.65 SLXP Score: +1,554.40

Their stock took a big hit a few months back when the FDA asked for more data on one of their drug trials. They have some drugs in their pipeline (stage 3 trials) that will cause the stock to recover as long as some of them pass. Undervalued at the current price.

Recs

0
Member Avatar reidmp (95.60) Submitted: 6/12/2008 10:57:14 AM : Outperform Start Price: $7.05 SLXP Score: +1,469.63

Over-reaction to FDA asking for more data after other problems. There have been too many high-profile drug safety stories in the media and it is logical to expect it will cause the FDA to be more cautious in handing out approvals. Solid insider purchasing and the recent trading pattern seems very stable and moving upward in a way that is much less erratic than seen in many biotech stocks.

Approval will help offset the genericization of COLAZAL. Also, Inflammatory diseases need better media coverage and consumer education. There is huge potential for improving quality of life for cronic conditions that can, without effective long-term management, shorten life expectancy. This could be a good company to monitor in that space.

Recs

0
Member Avatar caseykimma (67.69) Submitted: 4/7/2008 10:56:19 PM : Outperform Start Price: $7.09 SLXP Score: +1,461.21

several months or more..took a big hit in Jan08, slowly gaining back..Yahoo screener pick

Recs

0
Member Avatar StockLeader (75.75) Submitted: 3/20/2008 3:20:51 PM : Outperform Start Price: $6.60 SLXP Score: +1,577.06

Good Management and moving in the right direction

Recs

0
Member Avatar Foxyprox (94.51) Submitted: 2/12/2008 4:37:15 PM : Outperform Start Price: $6.58 SLXP Score: +1,585.35

Highly undervaled, great bargain in long run.

Recs

0
Member Avatar squiggley64 (95.81) Submitted: 2/1/2008 11:40:21 AM : Outperform Start Price: $6.81 SLXP Score: +1,529.31

All in the tract

Recs

0
Member Avatar lareineivre (90.47) Submitted: 12/30/2007 2:48:23 AM : Outperform Start Price: $8.24 SLXP Score: +1,246.47

Favorable risk / reward profile. Comparative analysis:
http://f1.grp.yahoofs.com/v1/8EF3R8IApDlbI1SUEwj9ACPoO-N506V3BymU7tTVdt21_4PxNLCn-oJ6KY_K8iQ5Z-yn652fM-b9S1MpHcVrFg/VOps/VOps%2007.11.30.xls

Recs

0
Member Avatar pscu (< 20) Submitted: 12/28/2007 6:30:49 PM : Underperform Start Price: $8.24 SLXP Score: -1,246.47

this stock killed me since i bought it at 16. the products are going nowhere. they lack luster. usually good stocks don't drop like this.

Recs

0
Member Avatar holopoj (46.00) Submitted: 12/10/2007 11:52:29 PM : Outperform Start Price: $11.98 SLXP Score: +816.72

Forbes article "True Believer Stocks"

Recs

0
Member Avatar wrath481 (42.76) Submitted: 6/30/2007 11:25:34 PM : Outperform Start Price: $12.30 SLXP Score: +790.02

Valuation at this level is good. Should be a 20 dollar stock in 2008. Institutional ownership is 105% according to Yahoo Finance... If the institutions are that confident, why aren't you?

Recs

0
Member Avatar MissDookN (< 20) Submitted: 5/14/2007 11:19:53 PM : Outperform Start Price: $12.72 SLXP Score: +758.51

This stock meets my criteria for a long-term buy: great management and a good price.

Recs

1
Member Avatar mnadel (96.84) Submitted: 4/8/2007 7:49:41 PM : Outperform Start Price: $13.40 SLXP Score: +706.92

OsmoPrep, Salix's new bowel cleansing product, is a true Rule Breaker. Previous prep products for colonoscopies have involved drinking a large volume of disgusting liquid (sometimes a gallon). OsmoPrep is an all-pill prep. It will be widely adopted, and not only will it pick up huge market share, it will expand the market. By making the prep easier, more people will get colonoscopies. The return of White House Spokesman Tony Snow's colon cancer will also highlight the need for the procedure. In light of this, Salix's earnings will explode -- not to mention their other products.

Recs

0
Member Avatar avi417 (74.20) Submitted: 10/19/2006 12:05:05 PM : Outperform Start Price: $14.74 SLXP Score: +619.53

great pipeline and some hot products coming to market i.e. xifaxan for crohn's

Results 1 - 20 of 20

Featured Broker Partners


Advertisement